This card contains **important safety information** you need to be aware of before you are given VFEND for prevention of fungal infections or during treatment with VFEND for your fungal infection.

If you do not understand this information, please ask your doctor to explain it to you.

Show this card to any doctor or healthcare professional involved in your care.

See the VFEND package leaflet for more information.

Call for Reporting:
As a reminder, there is a need to report any suspected adverse reactions to:
- The National Pharmacovigilance & Drug safety Centre (NPC) at Saudi Food and Drug Authority (SFDA):
SFDA Call Center: 19999
Toll Free Phone: 8002490000
Fax: +966-11-2057662
E-mail: npc.drug@sfda.gov.sa
Website: http://ade.sfda.gov.sa/

-Pharmacovigilance Department in the company:
E-mail: SAU.AEReporting@pfizer.com

شـــركة فايزر الســـعودية المحـدودة
Pfizer Saudi Limited
Scientific Office. No. 1010618064
King Abdullah Finacial District
Riyadh 13519
SAUDI ARABIA

VFEND® (Voriconazole)

Patient Alert Card

Please carry this card with you at all times

Version 2, December 2022

Other information (please complete):

Your name:

Date VFEND first prescribed:

Treating doctor's name:

Treatment centre name:

Treatment centre phone number:

PP-VFE-SAU-0064

You should avoid exposure to direct sunlight during VFEND treatment. It is important to cover sun exposed areas of skin and use sufficient sunscreen with high sun protection factor (SPF), as an increased sensitivity of skin to the sun's UV rays can occur. There is a small chance that skin cancer could develop over time.

You should contact your doctor immediately if you experience:
sunburn or severe skin reaction following exposure to light or sun.

Please ensure you **undergo all follow-up visits** for blood tests or skin evaluations arranged by your doctor. Please have a list of all your other medicines and medical conditions available at each visit to a healthcare professional.

For extra copies of patient alert card, please send an email with your contact details and the required amount to SAU.AEReporting@pfizer.com

This document is approved by the Executive Directorate of Pharmacovigilance at SFDA